Determinants of Virological Response to Antiretroviral Therapy: Implications for Long-Term Strategies
Open Access
- 1 June 2000
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 30 (Supplement) , S177-S184
- https://doi.org/10.1086/313855
Abstract
A variety of factors can contribute to the failure of combination antiretroviral therapy to durably suppress viral replication in patients infected with human immunodeficiency virus (HIV). Patients who have a low CD4+ T cell count or high plasma viral load before therapy is initiated are at high risk for subsequent virological failure. Previous therapy is also a strong determinant of subsequent virological response, presumably because of pre-existing viral resistance. Drug exposure, as determined by adherence, drug absorption, and drug metabolism, has a significant impact on future long-term virological responses. Although definitive proof is lacking, some tissues may have limited drug penetration, thus allowing for ongoing viral replication. Understanding why combination therapy fails for HIV-infected patients may allow clinicians to individualize treatment strategies. Unfortunately, almost any factor (drug, host, or viral) that leads to virological failure of an initial combination regimen is likely to persist—and perhaps become more challenging—once a salvage regimen is initiated.Keywords
This publication has 43 references indexed in Scilit:
- The Effects of Protease Inhibitor Therapy on Human Immunodeficiency Virus Type 1 Levels in Semen (AIDS Clinical Trials Group Protocol 850)The Journal of Infectious Diseases, 2000
- Sustained CD4+T Cell Response after Virologic Failure of Protease Inhibitor–Based Regimens in Patients with Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2000
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999
- A Randomized, Controlled Trial of Indinavir, Zidovudine, and Lamivudine in Adults with Advanced Human Immunodeficiency Virus Type 1 Infection and Prior Antiretroviral TherapyThe Journal of Infectious Diseases, 1999
- The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic responseAIDS, 1999
- Novel Four‐Drug Salvage Treatment Regimens after Failure of a Human Immunodeficiency Virus Type 1 Protease Inhibitor–Containing Regimen: Antiviral Activity and Correlation of Baseline Phenotypic Drug Susceptibility with Virologic OutcomeThe Journal of Infectious Diseases, 1999
- Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudineThe Lancet, 1998
- Kinetics of Response in Lymphoid Tissues to Antiretroviral Therapy of HIV-1 InfectionScience, 1997
- Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of DefectsScience, 1996
- Competition between zidovudine-sensitive and zidovudine-resistant strains of HIVAIDS, 1992